Danxin Wang

Danxin Wang, M.D., Ph.D.

Associate Professor

Department: Pharmacotherapy & Translational Research
Business Phone: (352) 273-7673
Business Email: danxin.wang@cop.ufl.edu

About Danxin Wang

Dr. Wang received her MD degree from Fudan University Medical School and her Ph.D from the Academy of Military Medical Science in Beijing. She did postdoctoral training at the University of California San Francisco. She was a Research Assistant Professor at Ohio State University, Department of Cancer Biology and Genetics and Associate Director of Center for Pharmacogenomics prior to joining the University of Florida.

Dr. Wang’s research interests are the discovery of genetic biomarkers for personalized drug therapy. She has discovered many functional regulatory variants in genes related to drug therapy in the areas of cardiovascular diseases, mental diseases and drug dependence. Some of these functional variants are currently included in biomarker testing panels to predict drug response.

Funded by NIH R01 and R35 awards, Dr. Wang’s current research is to understand factors controlling the expression of cytochrome P450 drug metabolizing enzymes (CYPs) in the liver. Using recently developed cutting edge functional genetics/genomics approaches, the research will focus on understanding what genetic, epigenetic and non-genetic factors may contribute to CYPs variability, with the goal to identify biomarker predicting enzyme activity of CYPs for guiding personalized drug therapy.

Dr. Wang has served as an Associate Editor of “European Journal of Pharmaceutical Sciences” and was on editorial Board of “Journal of Pharmacogenomics and Pharmacoproteomics”. She has also served as grant reviewer for NIH.

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0002-7134-3065

Areas of Interest
  • Drug Metabolism
  • Gene expression
  • Pharmacogenetics
  • Pharmacogenomics

Publications

2021
Co-expression of drug metabolizing cytochrome P450 enzymes and estrogen receptor alpha (ESR1) in human liver: racial differences and the regulatory role of ESR1.
Drug metabolism and personalized therapy. [DOI] 10.1515/dmpt-2020-0160. [PMID] 33823094.
2021
ESR1 ChIP-Seq Identifies Distinct Ligand-Free ESR1 Genomic Binding Sites in Human Hepatocytes and Liver Tissue.
International journal of molecular sciences. 22(3) [DOI] 10.3390/ijms22031461. [PMID] 33540646.
2021
Functional CYP3A variants affecting tacrolimus trough blood concentrations in Chinese renal transplant recipients.
The pharmacogenomics journal. 21(3):376-389 [DOI] 10.1038/s41397-021-00216-w. [PMID] 33649515.
2021
SIRT1 Gene SNP rs932658 Is Associated With Medication-Related Osteonecrosis of the Jaw.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 36(2):347-356 [DOI] 10.1002/jbmr.4185. [PMID] 32967053.
2020
Association of ANRIL Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation.
Anticancer research. 40(10):5707-5713 [DOI] 10.21873/anticanres.14585. [PMID] 32988896.
2020
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores.
CPT: pharmacometrics & systems pharmacology. 9(12):678-685 [DOI] 10.1002/psp4.12563. [PMID] 33067866.
2019
A comparison of genetic sampling methodologies for candidate-gene analyses.
Journal of translational science. 5(3) [DOI] 10.15761/JTS.1000306. [PMID] 31749990.
2019
Association of Regulatory Genetic Variants for Protein Kinase Cα with Mortality and Drug Efficacy in Patients with Heart Failure.
Cardiovascular drugs and therapy. 33(6):693-700 [DOI] 10.1007/s10557-019-06909-6. [PMID] 31728800.
2019
CYP2D6 haplotypes with enhancer single-nucleotide polymorphism rs5758550 and rs16947 (*2 allele): implications for CYP2D6 genotyping panels.
Pharmacogenetics and genomics. 29(2):39-47 [DOI] 10.1097/FPC.0000000000000363. [PMID] 30520769.
2019
Highly Variable Expression of ESR1 Splice Variants in Human Liver: Implication in the Liver Gene Expression Regulation and Inter-Person Variability in Drug Metabolism and Liver Related Diseases.
Journal of molecular and genetic medicine : an international journal of biomedical research. 13(3) [PMID] 32457812.
View on: PubMed
2019
Ligand-Free Estrogen Receptor α (ESR1) as Master Regulator for the Expression of CYP3A4 and Other Cytochrome P450 Enzymes in the Human Liver.
Molecular pharmacology. 96(4):430-440 [DOI] 10.1124/mol.119.116897. [PMID] 31399483.
2019
XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant.
Molecular carcinogenesis. 58(12):2327-2339 [DOI] 10.1002/mc.23121. [PMID] 31544312.
2018
Determining Allele-Specific Protein Expression (ASPE) Using a Novel Quantitative Concatamer Based Proteomics Method.
Journal of proteome research. 17(10):3606-3612 [DOI] 10.1021/acs.jproteome.8b00620. [PMID] 30141943.
2018
Estimation of Sobol’s Sensitivity Indices under Generalized Linear Models.
Communications in statistics: theory and methods. 47(21):5163-5195 [DOI] 10.1080/03610926.2017.1388397. [PMID] 30237653.
2018
Interactions Between Regulatory Variants in CYP7A1 (Cholesterol 7α-Hydroxylase) Promoter and Enhancer Regions Regulate CYP7A1 Expression.
Circulation. Genomic and precision medicine. 11(10) [DOI] 10.1161/CIRCGEN.118.002082. [PMID] 30354296.
2017
Intronic SNP in ESR1 encoding human estrogen receptor alpha is associated with brain ESR1 mRNA isoform expression and behavioral traits.
PloS one. 12(6) [DOI] 10.1371/journal.pone.0179020. [PMID] 28617822.
2017
Regulatory Variants Modulate Protein Kinase C α (PRKCA) Gene Expression in Human Heart.
Pharmaceutical research. 34(8):1648-1657 [DOI] 10.1007/s11095-017-2102-x. [PMID] 28120175.
2017
The CHRNA5/CHRNA3/CHRNB4 Nicotinic Receptor Regulome: Genomic Architecture, Regulatory Variants, and Clinical Associations.
Human mutation. 38(1):112-119 [DOI] 10.1002/humu.23135. [PMID] 27758088.
2016
CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing.
Pharmacogenetics and genomics. 26(1):40-3 [DOI] 10.1097/FPC.0000000000000183. [PMID] 26488616.
2016
Regulatory effects of genomic translocations at the human carboxylesterase-1 (CES1) gene locus.
Pharmacogenetics and genomics. 26(5):197-207 [DOI] 10.1097/FPC.0000000000000206. [PMID] 26871237.
2015
Allele-Selective Transcriptome Recruitment to Polysomes Primed for Translation: Protein-Coding and Noncoding RNAs, and RNA Isoforms.
PloS one. 10(9) [DOI] 10.1371/journal.pone.0136798. [PMID] 26331722.
2015
Analyzing allele specific RNA expression using mixture models.
BMC genomics. 16 [DOI] 10.1186/s12864-015-1749-0. [PMID] 26231172.
2015
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.
Clinical pharmacology and therapeutics. 98(1):19-24 [DOI] 10.1002/cpt.113. [PMID] 25801146.
2015
Conditional entropy in variation-adjusted windows detects selection signatures associated with expression quantitative trait loci (eQTLs).
BMC genomics. 16 Suppl 8 [DOI] 10.1186/1471-2164-16-S8-S8. [PMID] 26111110.
2015
Functional characterization of CYP2D6 enhancer polymorphisms.
Human molecular genetics. 24(6):1556-62 [DOI] 10.1093/hmg/ddu566. [PMID] 25381333.
2015
Regulation of cholesteryl ester transfer protein expression by upstream polymorphisms: reduced expression associated with rs247616.
Pharmacogenetics and genomics. 25(8):394-401 [DOI] 10.1097/FPC.0000000000000151. [PMID] 26061659.
2015
RNA sequencing of transcriptomes in human brain regions: protein-coding and non-coding RNAs, isoforms and alleles.
BMC genomics. 16 [DOI] 10.1186/s12864-015-2207-8. [PMID] 26597164.
2014
Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity.
Human molecular genetics. 23(1):268-78 [DOI] 10.1093/hmg/ddt417. [PMID] 23985325.
2014
Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.
Clinical pharmacology and therapeutics. 96(2):182-91 [DOI] 10.1038/clpt.2014.93. [PMID] 24781527.
2014
Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset.
Human molecular genetics. 23(8):1957-63 [DOI] 10.1093/hmg/ddt588. [PMID] 24282029.
2013
CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects.
Pharmacogenetics and genomics. 23(4):228-31 [DOI] 10.1097/FPC.0b013e32835e95c7. [PMID] 23376925.
2013
CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control.
Drug metabolism and drug interactions. 28(1):59-63 [DOI] 10.1515/dmdi-2012-0031. [PMID] 23314529.
2013
Regulatory polymorphisms in CYP2C19 affecting hepatic expression.
Drug metabolism and drug interactions. 28(1):23-30 [DOI] 10.1515/dmdi-2012-0038. [PMID] 23412869.
2012
Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk.
PloS one. 7(3) [DOI] 10.1371/journal.pone.0031930. [PMID] 22403620.
2012
CYP2C9 promoter variable number tandem repeat polymorphism regulates mRNA expression in human livers.
Drug metabolism and disposition: the biological fate of chemicals. 40(5):884-91 [DOI] 10.1124/dmd.111.044255. [PMID] 22289258.
2012
Polymorphisms of the SAMHD1 gene are not associated with the infection and natural control of HIV type 1 in Europeans and African-Americans.
AIDS research and human retroviruses. 28(12):1565-73 [DOI] 10.1089/AID.2012.0039. [PMID] 22530776.
2011
Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity.
Pharmacogenetics and genomics. 21(10):652-64 [DOI] 10.1097/FPC.0b013e3283498ee9. [PMID] 21878835.
2011
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs.
The pharmacogenomics journal. 11(4):274-86 [DOI] 10.1038/tpj.2010.28. [PMID] 20386561.
2011
Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 36(4):753-62 [DOI] 10.1038/npp.2010.208. [PMID] 21150907.
2011
Nicotinic α5 receptor subunit mRNA expression is associated with distant 5′ upstream polymorphisms.
European journal of human genetics : EJHG. 19(1):76-83 [DOI] 10.1038/ejhg.2010.120. [PMID] 20700147.
2011
Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy.
Clinical pharmacology and therapeutics. 89(3):355-65 [DOI] 10.1038/clpt.2010.314. [PMID] 21289622.
2010
Allele-specific tumor spectrum in pten knockin mice.
Proceedings of the National Academy of Sciences of the United States of America. 107(11):5142-7 [DOI] 10.1073/pnas.0912524107. [PMID] 20194734.
2009
CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response.
Circulation. Cardiovascular genetics. 2(4):362-70 [DOI] 10.1161/CIRCGENETICS.109.857839. [PMID] 20031608.
2009
Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia.
Brain : a journal of neurology. 132(Pt 2):417-25 [DOI] 10.1093/brain/awn248. [PMID] 18829695.
2009
Promoter polymorphisms in ACE (angiotensin I-converting enzyme) associated with clinical outcomes in hypertension.
Clinical pharmacology and therapeutics. 85(1):36-44 [DOI] 10.1038/clpt.2008.194. [PMID] 18946466.
2008
Genotyping panel for assessing response to cancer chemotherapy.
BMC medical genomics. 1 [DOI] 10.1186/1755-8794-1-24. [PMID] 18547414.
2008
Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues.
Pharmacogenetics and genomics. 18(9):781-91 [DOI] 10.1097/FPC.0b013e3283050107. [PMID] 18698231.
2008
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.
Blood. 112(4):1013-21 [DOI] 10.1182/blood-2008-03-144899. [PMID] 18523153.
2007
Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
The Journal of pharmacology and experimental therapeutics. 321(2):544-52 [PMID] 17267582.
View on: PubMed
2007
KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST).
Pharmacogenetics and genomics. 17(9):719-29 [PMID] 17700361.
View on: PubMed
2007
Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory.
Proceedings of the National Academy of Sciences of the United States of America. 104(51):20552-7 [PMID] 18077373.
View on: PubMed
2006
Calmodulin binding to peptides derived from the i3 loop of muscarinic receptors.
Pharmaceutical research. 23(4):647-53 [PMID] 16552497.
View on: PubMed
2006
Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues.
Pharmacogenetics and genomics. 16(10):735-45 [PMID] 17001293.
View on: PubMed
2006
Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1).
The AAPS journal. 8(3):E515-20 [PMID] 17025270.
View on: PubMed
2005
Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G.
The Journal of biological chemistry. 280(38):32618-24 [PMID] 16046395.
View on: PubMed
2005
Calmodulin interaction with peptides from G-protein coupled receptors measured with S-Tag labeling.
Biochemical and biophysical research communications. 333(2):390-5 [PMID] 15950946.
View on: PubMed
2005
In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice.
The Journal of pharmacology and experimental therapeutics. 313(3):1150-62 [PMID] 15716384.
View on: PubMed
2005
Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability.
Pharmacogenetics and genomics. 15(10):693-704 [PMID] 16141795.
View on: PubMed
2005
Opioid receptor homo- and heterodimerization in living cells by quantitative bioluminescence resonance energy transfer.
Molecular pharmacology. 67(6):2173-84 [PMID] 15778451.
View on: PubMed
2005
Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics.
Pharmacology & therapeutics. 106(1):19-38 [PMID] 15781120.
View on: PubMed
2004
Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence.
The Journal of pharmacology and experimental therapeutics. 308(2):512-20 [PMID] 14600246.
View on: PubMed
2002
Differential effects of mu-opioid receptor ligands on Ca(2+) signaling.
The Journal of pharmacology and experimental therapeutics. 302(3):1002-12 [PMID] 12183657.
View on: PubMed
2002
Serum response factor activation by muscarinic receptors via RhoA. Novel pathway specific to M1 subtype involving calmodulin, calcineurin, and Pyk2.
The Journal of biological chemistry. 277(43):40789-98 [PMID] 12200418.
View on: PubMed
2001
Genetic variations in human G protein-coupled receptors: implications for drug therapy.
AAPS pharmSci. 3(3) [PMID] 11741273.
View on: PubMed
2001
Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence.
Journal of neurochemistry. 77(6):1590-600 [PMID] 11413242.
View on: PubMed
2001
mu-Opioid receptor-mediated ERK activation involves calmodulin-dependent epidermal growth factor receptor transactivation.
The Journal of biological chemistry. 276(36):33847-53 [PMID] 11457825.
View on: PubMed
2001
Single nucleotide polymorphisms in the human mu opioid receptor gene alter basal G protein coupling and calmodulin binding.
The Journal of biological chemistry. 276(37):34624-30 [PMID] 11457836.
View on: PubMed
2000
Basal signaling activity of human dopamine D2L receptor demonstrated with an ecdysone-inducible mammalian expression system.
Journal of neuroscience methods. 94(2):217-25 [PMID] 10661841.
View on: PubMed
2000
Calmodulin regulation of basal and agonist-stimulated G protein coupling by the mu-opioid receptor (OP(3)) in morphine-pretreated cell.
Journal of neurochemistry. 75(2):763-71 [PMID] 10899953.
View on: PubMed
2000
G-protein coupling of mu-opioid receptors (OP3): elevated basal signalling activity.
The Biochemical journal. 348 Pt 3:531-7 [PMID] 10839983.
View on: PubMed
2000
Nuclear Ca2+/calmodulin translocation activated by mu-opioid (OP3) receptor.
Journal of neurochemistry. 74(4):1418-25 [PMID] 10737597.
View on: PubMed
1999
3-Isobutyl-1-methylxanthine inhibits basal mu-opioid receptor phosphorylation and reverses acute morphine tolerance and dependence in mice.
European journal of pharmacology. 371(1):1-9 [PMID] 10355588.
View on: PubMed
1999
Calmodulin binding to G protein-coupling domain of opioid receptors.
The Journal of biological chemistry. 274(31):22081-8 [PMID] 10419536.
View on: PubMed
1996
[Binding of [3H] dihydroetorphine to opioid receptors in rat brain membrane].
Zhongguo yao li xue bao = Acta pharmacologica Sinica. 17(3):281-3 [PMID] 9812759.
View on: PubMed
1995
Dihydroetorphine is a mu-receptor-selective ligand.
The Journal of pharmacy and pharmacology. 47(8):669-73 [PMID] 8583370.
View on: PubMed
1991
[Effect of dihydroetorphine on contraction response of guinea pig ileum, mouse, and rabbit vas deferens induced by electric field stimulation in vitro].
Zhongguo yao li xue bao = Acta pharmacologica Sinica. 12(5):420-2 [PMID] 1687907.
View on: PubMed

Grants

Apr 2021 ACTIVE
Expression genetics of pharmacogenes
Role: Principal Investigator
Funding: NATL INST OF HLTH NIGMS
May 2018 ACTIVE
Expression Genetics of CYP3A Drug Metabolizing Enzymes
Role: Principal Investigator
Funding: NATL INST OF HLTH NIGMS
May 2018 – Apr 2021
Translational candidate-gene studies of simvastatin-induced myopathy in African Americans
Role: Principal Investigator
Funding: OHIO STATE UNIV via NATL INST OF HLTH NIMHD
May 2018 – Jan 2021
Genetic determinants of ACEI prodrug activation
Role: Principal Investigator
Funding: UNIV OF MICHIGAN via NATL INST OF HLTH NHLBI

Education

Ph.D.
1999 · Academy of Military Medical Sciences
M.S.
1988 · Fudan University Medical School
M.D.
1985 · Fudan University Medical School

Teaching Profile

Courses Taught
2020
PHA6427 Pharmacogenetics of Drug Metabolism
2020-2021
PHA6935 Selected Topics in Pharmacy
2018-2020
PHA6134 Foundations in Precision Medicine: Genomic Technologies
2020
PHA5930 Sem Pharm Research

Contact Details

Phones:
Business:
(352) 273-7673
Emails: